Table 1 Clinical characteristics of the patients or control individuals, who received a muscle biopsy.
From: Skeletal muscle derived Musclin protects the heart during pathological overload
Control N = 9 | Sarcopenic N = 6 | Cachectic N = 5 | |
|---|---|---|---|
Age (years) | 56.08 ± 24.05 | 68.3 ± 5.5 | 55.6 ± 8.7 |
Male/Female n (%) | 5/4 (56/44) | 5/1 (83/17) | 4/1 (80/20) |
BMI (g/m2) | 24.47 ± 2.87 | 24.0 ± 4.3 | 29.1 ± 8.5 |
Weight (kg) | 72.4 ± 12.79 | 70.5 ± 15.3 | 87.7 ± 23 |
Weight loss 1 year (kg) | 0.33 ± 0.58 (n = 3) | −1 ± 2.9 | 5.1 ± 1.6* |
Diabetes mellitus | 0 | 2 (28.6%) | 2 (40.0%) |
Echocardiography | |||
Ejection fraction (%) | 61.88 ± 3.13 | 32.5 ± 9.4**** | 32 ± 7.6**** |
Clinical classification [% of all patients] | |||
NYHA I | N/A | 2 (33.3%) | 1 (20%) |
NYHA II | N/A | 2 (33.3%) | 3 (60%) |
NYHA III | N/A | 1 (16.7%) | 1 (20%) |
NYHA IV | N/A | 1 (16.7%) | 0 (0%) |
Medication [% of all patients] | |||
ACE inhibitor | 2 (40%) | 4 (66.7%) | 4 (80%) |
Angiotensin receptor antagonist | None | 2 (33.3%) | 1 (20%) |
β-receptor antagonist | None | 6 (100%) | 5 (100%) |
Diuretic | None | 3 (50%) | 2 (40%) |
Calcium channel antagonist | 1 (20%) | 1 (16.7%) | 1 (20 %) |
